Measurement of the top quark charge in pp collisions at sqrts = 7 TeV with the ATLAS detector

A measurement of the top quark electric charge is carried out in the ATLAS experiment at the Large Hadron Collider using 2.05 fb-1 of data at a centre-of-mass energy of 7 TeV. In units of the elementary electric charge, the top quark charge is determined to be 0.64 +- 0.02 (stat.) +- 0.08 (syst.) from the charges of the top quark decay products in single lepton ttbar candidate events. This excludes models that propose a heavy quark of electric charge --4/3, instead of the Standard Model top quark, with a significance of more than 8 sigma.

Lack of fifth anchoring point and violation of the insertion of the rotator cuff during antegrade humeral nailing: pitfalls in straight antegrade humeral nailing.

Antegrade nailing of proximal humeral fractures using a straight nail can damage the bony insertion of the supraspinatus tendon and may lead to varus failure of the construct. In order to establish the ideal anatomical landmarks for insertion of the nail and their clinical relevance we analysed CT scans of bilateral proximal humeri in 200 patients (mean age 45.1 years (sd 19.6; 18 to 97) without humeral fractures. The entry point of the nail was defined by the point of intersection of the anteroposterior and lateral vertical axes with the cortex of the humeral head. The critical point was defined as the intersection of the sagittal axis with the medial limit of the insertion of the supraspinatus tendon on the greater tuberosity. The region of interest, i.e. the biggest entry hole that would not encroach on the insertion of the supraspinatus tendon, was calculated setting a 3 mm minimal distance from the critical point. This identified that 38.5% of the humeral heads were categorised as 'critical types', due to morphology in which the predicted offset of the entry point would encroach on the insertion of the supraspinatus tendon that may damage the tendon and reduce the stability of fixation. We therefore emphasise the need for 'fastidious' pre-operative planning to minimise this risk.

The AEgIS experiment at CERN for the measurement of antihydrogen gravity acceleration

The Antihydrogen Experiment: Gravity, Interferometry, Spectroscopy (AEgIS) experiment is conducted by an international collaboration based at CERN whose aim is to perform the first direct measurement of the gravitational acceleration of antihydrogen in the local field of the Earth, with Δg/g = 1% precision as a first achievement. The idea is to produce cold (100 mK) antihydrogen ( ¯H) through a pulsed charge exchange reaction by overlapping clouds of antiprotons, from the Antiproton Decelerator (AD) and positronium atoms inside a Penning trap. The antihydrogen has to be produced in an excited Rydberg state to be subsequently accelerated to form a beam. The deflection of the antihydrogen beam can then be measured by using a moir´e deflectometer coupled to a position sensitive detector to register the impact point of the anti-atoms through the vertex reconstruction of their annihilation products. After being approved in late 2008, AEgIS started taking data in a commissioning phase in 2012. This paper presents an outline of the experiment with a brief overview of its physics motivation and of the state-of-the-art of the g measurement on antimatter. Particular attention is given to the current status of the emulsion-based position detector needed to measure the ¯H sag in AEgIS.

Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.

PURPOSE Rituximab maintenance therapy has been shown to improve progression-free survival in patients with follicular lymphoma; however, the optimal duration of maintenance treatment remains unknown. PATIENTS AND METHODS Two hundred seventy patients with untreated, relapsed, stable, or chemotherapy-resistant follicular lymphoma were treated with four doses of rituximab monotherapy in weekly intervals (375 mg/m(2)). Patients achieving at least a partial response were randomly assigned to receive maintenance therapy with one infusion of rituximab every 2 months, either on a short-term schedule (four administrations) or a long-term schedule (maximum of 5 years or until disease progression or unacceptable toxicity). The primary end point was event-free survival (EFS). Progression-free survival, overall survival (OS), and toxicity were secondary end points. Comparisons between the two arms were performed using the log-rank test for survival end points. RESULTS One hundred sixty-five patients were randomly assigned to the short-term (n = 82) or long-term (n = 83) maintenance arms. Because of the low event rate, the final analysis was performed after 95 events had occurred, which was before the targeted event number of 99 had been reached. At a median follow-up period of 6.4 years, the median EFS was 3.4 years (95% CI, 2.1 to 5.3) in the short-term arm and 5.3 years (95% CI, 3.5 to not available) in the long-term arm (P = .14). Patients in the long-term arm experienced more adverse effects than did those in the short-term arm, with 76% v 50% of patients with at least one adverse event (P < .001), five versus one patient with grade 3 and 4 infections, and three versus zero patients discontinuing treatment because of unacceptable toxicity, respectively. There was no difference in OS between the two groups. CONCLUSION Long-term rituximab maintenance therapy does not improve EFS, which was the primary end point of this trial, or OS, and was associated with increased toxicity.